Magnetic introduction quantum dot patch as well as preparation method and application thereof

Abstract

The invention belongs to the technical field of medical instruments, and particularly relates to a magnetic introduction quantum dot patch as well as a preparation method and application thereof. The quantum dots are introduced into the application, the quantum dots are combined with the medicine, and the quantum dots can effectively enter the human body in the magnetic line direction under the action of the magnetic field generator; the electron radiation source absorbs heat of a human body to emit far infrared rays, electrons in the quantum dots are excited to transition, electromagnetic waves with specific wavelengths are emitted, the quantum dot drug compound releases drugs, meanwhile, the electromagnetic waves and magnetic field energy waves of human cells can form resonance and conduction, damaged cells are repaired, cell energy is supplemented, and treatment is achieved. When the magnetic introduction quantum dot application provided by the invention is used for treating human body diseases, accurate treatment on the human body diseases is realized by combining the microparticle characteristics and high-frequency energy wave characteristics of quantum dots and the biological effect of a magnetic field, and the magnetic introduction quantum dot application has a remarkable treatment effect, is wide in application range and is simple and convenient to operate.

Description

Technical Field

[0001] The present invention belongs to the technical field of medical devices, and particularly relates to a magnetic induction quantum dot patch and its preparation method and application. Background Art

[0002] Magnetic field therapy, abbreviated as magnetotherapy, is a method of applying a magnetic field to the human body to treat diseases. The magnetic field can change the magnitude and direction of the bioelectric current in the human body, generate weak eddy currents, and affect the direction of electron movement in the body and the distribution, concentration, and movement speed of ions inside and outside cells, thereby producing a series of biological effects on the human body. However, the treatment effect of traditional magnetic field therapy is uncertain, and other treatment methods need to be combined to achieve better results. Summary of the Invention

[0003] In view of this, the present invention provides a magnetic induction quantum dot patch and its preparation method and application. The patch provided by the present invention has a good magnetic induction effect and a significant treatment effect.

[0004] To solve the above technical problems, the present invention provides a magnetic induction quantum dot patch, which includes a first patch or a second patch;

[0005] The first patch includes an adhesive layer and a magnetic field generating layer, an electron radiation layer, a quantum dot drug complex layer, a controlled release membrane layer, and a first release substrate stacked in sequence; the middle part of the adhesive layer is in contact with the magnetic field generating layer, and the edge part of the adhesive layer covers the sides of the magnetic field generating layer, the electron radiation layer, the quantum dot drug complex layer, and the controlled release membrane layer and the remaining upper surface of the first release substrate; the quantum dot drug complex layer includes a first quantum dot drug complex, and the first quantum dot drug complex includes a carrier and a complex loaded on the surface of the carrier, and the complex includes a first quantum dot and a first drug bound to the first quantum dot;

[0006] The second patch includes a protective layer, a magnetic induction layer, a sustained release layer, and a second release substrate stacked in sequence; the magnetic induction layer includes a second magnetic field generator and a second electron radiation source dispersed in the second magnetic field generator; the sustained release layer includes a second controlled release membrane and a second quantum dot drug complex dispersed in the second controlled release membrane, and the second quantum dot drug complex includes a second quantum dot and a second drug bound to the second quantum dot.

[0007] Preferably, the adhesive layer includes a first substrate and a first adhesive coated on the surface of the first substrate, and the first substrate includes non-woven fabric, polyurethane, polyethylene, or polyvinyl chloride; the first adhesive includes pressure-sensitive adhesive, acrylic adhesive, silicone gel, or hydrogel;

[0008] The protective layer includes a second substrate and a second binder coated on the surface of the second substrate. The second substrate includes non-woven fabric, polyurethane, polyethylene or polyvinyl chloride; the second binder includes pressure-sensitive adhesive, acrylic adhesive, silicone gel or hydrogel.

[0009] Preferably, the magnetic field generating layer includes a first magnetic field generator; the first magnetic field generator and the second magnetic field generator each include a permanent magnetic material;

[0010] The first magnetic field generator and the second magnetic field generator each include a multi-pole magnetic circuit, and the number of poles of the magnetic circuit is 4 poles or more;

[0011] The magnetic induction intensities of the first magnetic field generator and the second magnetic field generator are independently 5 to 100 mT.

[0012] Preferably, the electron radiation layer includes a first electron radiation source; the first electron radiation source and the second electron radiation source independently include one or more of far-infrared ceramic powder, tourmaline and graphene.

[0013] Preferably, the first quantum dot and the second quantum dot independently include one or more of iron sulfide quantum dots, superparamagnetic Fe 3 O 4 @alginate carbon quantum dots, doped zinc sulfide quantum dots, perovskite quantum dots, silver chalcogenide quantum dots, copper indium sulfide quantum dots, iron sulfide quantum dots, carbon quantum dots, graphene quantum dots and ferrite quantum dots;

[0014] The ligands in the first quantum dot and the second quantum dot independently include mercaptoacetic acid, mercaptoethylamine or polyethylene glycol;

[0015] The first drug and the second drug independently include plant extracts, tramadol, NSAIDs, melatonin, salbutamol;

[0016] The carrier includes hydrogel, liposome, poly(lactic-co-glycolic acid) nanospheres or poly(D,L-lactic acid) nanospheres.

[0017] Preferably, the controlled release membrane layer includes a first controlled release membrane, and the first controlled release membrane includes a stretched polypropylene microporous membrane;

[0018] The material of the second controlled release membrane includes ethylene-vinyl acetate copolymer, hydrocolloid or silicone gel.

[0019] The present invention also provides a preparation method of the magnetic induction quantum dot patch according to the above technical solution, including the following steps:

[0020] The preparation method of the first patch includes the following steps:

[0021] Coat a first adhesive on the surface of a first substrate to obtain an adhesive layer;

[0022] Mix a first permanent magnetic material, a first rubber, a first resin, and a first auxiliary agent and then mold them to obtain a magnetic field generating layer;

[0023] Mix a glycerol solution of polyvinylpyrrolidone and crosslinked polyvinylpyrrolidone, polyacrylic acid colloid, tartaric acid, a first electron radiation source, water, and a crosslinking agent and then mold them to obtain an electron radiation layer;

[0024] Stack the adhesive layer, the magnetic field generator, and the electron radiation layer in sequence, and then coat a first dispersion liquid on the surface of the electron radiation layer to form a quantum dot drug composite layer; the first dispersion liquid includes a first quantum dot, a carrier, a first drug, and water;

[0025] Paste a controlled release membrane layer and a first release liner substrate on the surface of the quantum dot drug composite layer in sequence to obtain the first patch;

[0026] The preparation method of the second patch includes the following steps:

[0027] Coat a second adhesive on the surface of a second substrate to obtain a protective layer;

[0028] Mix a second permanent magnetic material, a second electron radiation source, a second rubber, a second resin, and a second auxiliary agent and then mold them to obtain a magnetic induction layer;

[0029] Mix a second quantum dot, a second drug, a sustained release agent, and water and then mold them to obtain a sustained release layer;

[0030] Stack the protective layer, the magnetic induction layer, the sustained release layer, and a second release liner substrate to obtain the second patch.

[0031] Preferably, the first resin includes chlorinated polyethylene resin;

[0032] The first auxiliary agent includes dioctyl phthalate, sulfur, or titanate coupling agent;

[0033] The crosslinking agent includes aluminum glycinate.

[0034] Preferably, the second resin includes epoxy resin;

[0035] The second auxiliary agent includes adipate, zinc oxide, or titanate coupling agent;

[0036] The sustained release agent includes ethylene-vinyl acetate copolymer, hydrocolloid, or silicone gel.

[0037] The present invention also provides the use of the magnetically introduced quantum dot patch described in the above technical solution or the magnetically introduced quantum dots prepared by the preparation method described in the above technical solution in the preparation of drugs for treating soft tissue injuries, promoting blood circulation to remove blood stasis, detumescence and pain relief, sarcoidosis, tranquilizing and hypnotizing, or relieving asthma and cough.

[0038] The present invention provides a magnetically introduced quantum dot patch, which includes a first patch or a second patch; the first patch includes a paste layer, a magnetic field generating layer, an electron radiation layer, a quantum dot drug complex layer, a controlled release membrane layer, and a first release substrate stacked in sequence; the middle part of the paste layer is in contact with the magnetic field generating layer, and the edge part of the paste layer covers the sides of the magnetic field generating layer, the electron radiation layer, the quantum dot drug complex layer, and the controlled release membrane layer, as well as the remaining upper surface of the first release substrate; the quantum dot drug complex layer includes a first quantum dot drug complex, and the first quantum dot drug complex includes a carrier and a complex loaded on the surface of the carrier, and the complex includes a first quantum dot and a first drug bound to the first quantum dot; the second patch includes a protective layer, a magnetic induction layer, a sustained release layer, and a second release substrate stacked in sequence; the magnetic induction layer includes a second magnetic field generator and a second electron radiation source dispersed in the second magnetic field generator; the sustained release layer includes a second controlled release membrane and a second quantum dot drug complex dispersed in the second controlled release membrane, and the second quantum dot drug complex includes a second quantum dot and a second drug bound to the second quantum dot. The present invention introduces quantum dots into the patch, combines the quantum dots with drugs, and can effectively enter the human body along the direction of the magnetic force line under the action of the magnetic field generator; the electron radiation source absorbs the heat of the human body and emits far-infrared rays, which excite the electron transition in the quantum dots, resulting in the emission of electromagnetic waves with specific wavelengths, so that the quantum dot drug complex releases the drug. At the same time, the electromagnetic waves and the magnetic field energy waves of human cells can form resonance and conduction, repair damaged cells, and supplement cell energy to achieve treatment. When using the magnetically introduced quantum dot patch provided by the present invention to treat human diseases, by combining the microparticle characteristics and high-frequency energy wave characteristics of quantum dots and the biological effects of magnetic fields, precise treatment of human diseases is achieved, with remarkable treatment effects, wide application range, and simple operation. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] Figure 1 It is a schematic structural diagram of the magnetically introduced quantum dot patch prepared in Example 1, where 1 is the bonding layer, 2 is the magnetic generation layer, 3 is the electron radiation layer, 4 is the quantum dot drug complex layer, 5 is the controlled release membrane layer, and 6 is the first release substrate;

[0040] Figure 2 It is a schematic structural diagram of the magnetically introduced quantum dot patch prepared in Example 2, where 7 is the protective layer, 8 is the second magnetic generator, 9 is the second electron radiation source, 10 is the second quantum dot drug complex, 11 is the second controlled release membrane, and 12 is the second release substrate;

[0041] Figure 3 Schematic diagram of the magnetic field generated by the magnetic induction quantum dot patch provided by the present invention. Detailed implementation manners

[0042] The present invention provides a magnetic induction quantum dot patch, which includes a first patch or a second patch.

[0043] In the present invention, the first patch includes a paste layer, a magnetic field generating layer, an electron radiation layer, a quantum dot drug complex layer, a controlled release membrane layer and a first release substrate stacked in sequence; the middle part of the paste layer is in contact with the magnetic field generating layer, and the edge part of the paste layer covers the sides of the magnetic field generating layer, the electron radiation layer, the quantum dot drug complex layer and the controlled release membrane layer and the remaining upper surface of the first release substrate; the present invention adheres to the human body through the edge of the paste layer. As a specific implementation manner of the present invention, the paste layer includes a first substrate and a first binder coated on the surface of the first substrate, and the first substrate includes non-woven fabric, polyurethane (PU), polyethylene (PE) or polyvinyl chloride (PVC); the first binder includes pressure-sensitive adhesive, acrylic adhesive, silicone gel or hydrogel; the first binder is directly in contact with the magnetic field generating layer. As a specific implementation manner of the present invention, the thickness of the paste layer can be 0.15-0.2 mm, and can specifically be 0.15 mm, 0.18 mm or 0.2 mm.

[0044] As a specific implementation manner of the present invention, the magnetic field generating layer includes a first magnetic field generator; the first magnetic field generator can include a permanent magnetic material, and the permanent magnetic material can be a neodymium iron boron permanent magnet and / or a ferrite permanent magnet, and can specifically be a mixture of a neodymium iron boron permanent magnet and a ferrite permanent magnet, a neodymium iron boron permanent magnet or a ferrite permanent magnet; the first magnetic field generator can include a multi-pole magnetic circuit, and the number of poles of the magnetic circuit can be more than 4 poles, and can also be 10-18 poles; the multi-pole magnetic circuit utilizes the characteristic that the magnetic force lines tend to select the shortest path to connect the opposite poles. Compared with the single-pole magnetic circuit, the magnetic force lines of the multi-pole magnetic circuit are more concentrated on the surface of the magnet, the magnetic induction intensity is large, and the more poles there are, the more obvious the effect is and the stronger the magnetic induction effect is.

[0045] As a specific implementation manner of the present invention, the pole width of the first magnetic field generator can be 2-4 mm, and can specifically be 2 mm, 3 mm or 4 mm; the present invention can determine the number of poles of the magnetic circuit according to the size of the patch. As a specific implementation manner of the present invention, the magnetic induction intensity of the first magnetic field generator can be 5-100 mT, can also be 10-80 mT, and can further be 30-60 mT. As a specific implementation manner of the present invention, the thickness of the magnetic field generating layer can be 0.2-1.5 mm, and can also be 0.5-1.0 mm.

[0046] As a specific embodiment of the present invention, the electron radiation layer may include a first electron radiation source; the first electron radiation source may include one or more of far-infrared ceramic powder, tourmaline, and graphene, and may specifically be far-infrared ceramic powder, tourmaline, or graphene; the average particle size of the far-infrared ceramic powder may be 2 to 4 μm, the average particle size of the tourmaline may be 100 to 800 mesh, and the average particle size of the graphene may be 5 μm. As a specific embodiment of the present invention, the thickness of the electron radiation layer may be 0.1 to 1.5 mm, and may also be 0.2 to 1 mm.

[0047] As a specific embodiment of the present invention, the quantum dot drug complex layer includes a first quantum dot drug complex, and the first quantum dot drug complex includes a carrier and a complex loaded on the carrier, and the complex includes a first quantum dot and a first drug bound to the first quantum dot. As a specific embodiment of the present invention, the carrier may include a hydrogel, a liposome, a poly(lactic-co-glycolic acid) (PLGA) nanosphere, or a poly(D,L-lactic acid) (PLA) nanosphere. As a specific embodiment of the present invention, the first quantum dot may include a ferrous sulfide quantum dot (FeS), superparamagnetic Fe 3 O 4 @alginate carbon quantum dots, doped zinc sulfide quantum dots (ZnS), perovskite quantum dots, silver chalcogenide quantum dots, copper indium sulfide quantum dots (CuInS 2 )), iron sulfide quantum dots (FeS QD), carbon quantum dots, graphene quantum dots, and ferrite quantum dots (Fe 3 O 4 QD) or one or more of them, and may specifically be ferrous sulfide quantum dots, superparamagnetic Fe 3 O 4 @alginate carbon quantum dots, doped zinc sulfide quantum dots, perovskite quantum dots, silver chalcogenide quantum dots, copper indium sulfide quantum dots, iron sulfide quantum dots, carbon quantum dots, graphene quantum dots, or ferrite quantum dots; the ligand in the first quantum dot may include mercaptoacetic acid, mercaptoethylamine, or polyethylene glycol (PEG). As a specific embodiment of the present invention, the superparamagnetic Fe 3 O 4 @alginate carbon quantum dots can be prepared according to the following method:

[0048] Dissolve ferric salt and ferrous salt in water, and then adjust the pH value to 10 to 11 at 70 to 80 °C under a protective atmosphere to obtain magnetite particles;

[0049] Dissolve sodium alginate in water for hydrothermal reaction to obtain a sodium alginate carbon quantum dot solution;

[0050] Disperse the magnetite particles in water and then mix with the sodium alginate carbon quantum dot solution to obtain the superparamagnetic Fe 3 O 4 @alginate carbon quantum dots.

[0051] In the present invention, ferric salts and ferrous salts are dissolved in water, and then the pH value is adjusted to 10-11 at 70-80 °C under a protective atmosphere to obtain magnetite particles. As a specific embodiment of the present invention, the ferric salt may be FeCl 3 ·6H 2 O, the ferrous salt may be FeCl 2 ·4H 2 O, and the water may be deionized water; the molar ratio of the ferric salt to the ferrous salt may be 1.8-2.2:1, specifically 2:1; there are no special requirements for the dissolution in the present invention, as long as it can be completely dissolved. As a specific embodiment of the present invention, the protective atmosphere may be nitrogen; stirring may be accompanied during heating to 70-80 °C and adjusting the pH value; the pH value regulator used for adjusting the pH value may be ammonia water, and there are no special limitations on the concentration and dosage of the ammonia water in the present invention, as long as the required pH value can be achieved. As a specific embodiment of the present invention, after adjusting the pH value to 10-11, it may further include: performing magnetic separation on the system after adjusting the pH value, and sequentially washing, ethanol washing, and drying the solid obtained by magnetic separation to obtain magnetite particles; the water used for washing may be deionized water; there are no special limitations on the drying in the present invention, as long as the solvent on the solid surface can be removed.

[0052] In the present invention, sodium alginate is dissolved in water for hydrothermal reaction to obtain a sodium alginate carbon quantum dot solution. As a specific embodiment of the present invention, the water may be deionized water, and there are no special requirements for the dissolution in the present invention, as long as it can be completely dissolved. As a specific embodiment of the present invention, the temperature of the hydrothermal reaction may be 180-200 °C, or 185-195 °C; the time of the hydrothermal reaction may be 4-6 h, or 4.5-5.5 h. As a specific embodiment of the present invention, after the hydrothermal reaction, it may further include: cooling the system after the hydrothermal reaction to room temperature and then centrifuging to obtain the sodium alginate carbon quantum dot solution; the temperature of the room temperature may be 20-35 °C, or 25-30 °C; in the present invention, large particles in the system can be removed by centrifugation, and there are no special limitations on the centrifugation in the present invention as long as the large particles can be removed.

[0053] After obtaining the magnetite particles and the sodium alginate carbon quantum dot solution, in the present invention, the magnetite particles are dispersed in water and then mixed with the sodium alginate carbon quantum dot solution to obtain the superparamagnetic Fe 3O 4 @Alginate carbon quantum dots. As a specific embodiment of the present invention, the water can be deionized water; the dispersion can be carried out under ultrasonic conditions; the present invention has no special limitation on the ultrasonic, as long as it can be evenly dispersed. As a specific embodiment of the present invention, the mixing can be carried out under stirring conditions, and the stirring time can be 12 to 24 h, or can also be 15 to 20 h. The present invention has no special requirement for the stirring speed, as long as it can be evenly mixed. As a specific embodiment of the present invention, after the mixing, it may further include: performing magnetic separation on the mixed system; washing and drying the solid obtained by the magnetic separation in sequence to obtain the superparamagnetic Fe 3 O 4 @Alginate carbon quantum dots. As a specific embodiment of the present invention, the water used for washing can be deionized water. The present invention has no special limitation on the drying, as long as the solvent on the surface of the solid can be removed.

[0054] As a specific embodiment of the present invention, the first drug can include plant extracts, tramadol, NSAIDs, melatonin or salbutamol, the plant extract can be wormwood extract, and the wormwood extract can be wormwood essential oil; the way the first drug binds to the first quantum dot can include coupling with the ligand in the first quantum dot or electrostatic interaction. As a specific embodiment of the present invention, the thickness of the quantum dot drug complex layer can be 0.03 to 2.00 mm, or can also be 0.05 to 1.00 mm.

[0055] As a specific embodiment of the present invention, the controlled release membrane layer can include a first controlled release membrane, and the first controlled release membrane can include a polypropylene stretched microporous membrane. As a specific embodiment of the present invention, the thickness of the controlled release membrane layer can be 10 to 250 μm, or can also be 20 to 200 μm.

[0056] As a specific embodiment of the present invention, the first release liner substrate can include a release film.

[0057] As a specific embodiment of the present invention, the structural schematic diagram of the first patch is as Figure 1 shown, where 1 is the adhesive layer, 2 is the magnetic generation layer, 3 is the electron radiation layer, 4 is the quantum dot drug complex layer, 5 is the controlled release membrane layer, and 6 is the first release liner substrate.

[0058] In the present invention, the second patch includes a protective layer, a magnetic induction layer, a sustained-release layer, and a second release substrate, which are stacked in sequence. As a specific embodiment of the present invention, the protective layer may include a second substrate and a second adhesive coated on the surface of the second substrate. The second substrate may include non-woven fabric, polyurethane (PU), polyethylene (PE), or polyvinyl chloride (PVC); the second adhesive may include pressure-sensitive adhesive, acrylic adhesive, silicone gel, or hydrogel; the second adhesive is in direct contact with the magnetic induction layer. As a specific embodiment of the present invention, the thickness of the protective layer may be 0.2 to 7 mm, and may also be 1 to 5 mm.

[0059] As a specific embodiment of the present invention, the magnetic induction layer includes a second magnetic field generator and a second electron radiation source dispersed in the second magnetic field generator; the second magnetic field generator may include a permanent magnetic material, and the permanent magnetic material may be a neodymium iron boron permanent magnet and / or a ferrite permanent magnet; the second magnetic field generator may include a multi-pole magnetic circuit, and the number of poles of the magnetic circuit may be more than 4 poles, and may also be 10 to 50 poles, and may further be 18 to 40 poles; the multi-pole magnetic circuit utilizes the characteristic that magnetic lines of force tend to select the shortest path to connect opposite poles. Compared with a single-pole magnetic circuit, the magnetic lines of force of the multi-pole magnetic circuit are more concentrated on the surface of the magnet, the magnetic induction intensity is large, and the more poles there are, the more obvious the effect and the stronger the magnetic induction effect. As a specific embodiment of the present invention, the pole width of the second magnetic field generator may be 2 to 4 mm, and may specifically be 2 mm, 3 mm, or 4 mm. As a specific embodiment of the present invention, the magnetic induction intensity of the second magnetic field generator may be 5 to 100 mT, and may also be 10 to 80 mT, and may further be 20 to 50 mT. As a specific embodiment of the present invention, the second electron radiation source may include one or more of far-infrared ceramic powder, tourmaline, and graphene, and may specifically be far-infrared ceramic powder, tourmaline, or graphene; the average particle size of the far-infrared ceramic powder may be 2 to 4 μm, the average particle size of the tourmaline may be 100 to 800 mesh, and the average particle size of the graphene may be 5 μm. As a specific embodiment of the present invention, the thickness of the magnetic induction layer may be 0.1 to 2.0 mm, and may also be 0.5 to 1 mm.

[0060] As a specific embodiment of the present invention, the sustained-release layer includes a second controlled-release membrane and a second quantum dot drug complex dispersed in the second controlled-release membrane. The second quantum dot drug complex includes a second quantum dot and a second drug bound to the second quantum dot. As a specific embodiment of the present invention, the material of the second controlled-release membrane may include ethylene-vinyl acetate copolymer (EVA), hydrocolloid, or silicone gel. As a specific embodiment of the present invention, the second quantum dot may include iron sulfide quantum dots (FeS), superparamagnetic Fe 3 O4 @Alginate carbon quantum dots, doped zinc sulfide quantum dots (ZnS), perovskite quantum dots, silver chalcogenide quantum dots, copper indium sulfide quantum dots (CuInS 2 )、iron sulfide quantum dots (FeS QD), carbon quantum dots, graphene quantum dots, and ferrite quantum dots (Fe 3 O 4 QD), one or more of which may specifically be ferrous sulfide quantum dots, superparamagnetic Fe 3 O 4 @Alginate carbon quantum dots, doped zinc sulfide quantum dots, perovskite quantum dots, silver chalcogenide quantum dots, copper indium sulfide quantum dots, iron sulfide quantum dots, carbon quantum dots, graphene quantum dots, or ferrite quantum dots; the ligands in the second quantum dots may include mercaptoacetic acid, mercaptoethylamine, or polyethylene glycol (PEG); the second drug may include plant extracts, tramadol, NSAIDs, melatonin, salbutamol, and the plant extract may be wormwood extract; the manner in which the second drug binds to the second quantum dots may include coupling with the ligands in the second quantum dots or electrostatic interaction. As a specific embodiment of the present invention, the thickness of the sustained-release layer may be 0.2 to 1.5 mm, and may also be 0.5 to 1 mm. In the present invention, as the second quantum dots, superparamagnetic Fe 3 O 4 @The preparation method of alginate carbon quantum dots may be the same as that of superparamagnetic Fe 3 O 4 @alginate carbon quantum dots as the first quantum dots, and will not be repeated here.

[0061] As a specific embodiment of the present invention, the second release substrate may include a release film.

[0062] As a specific embodiment of the present invention, the structural schematic diagram of the second patch is as Figure 2 shown, where 7 is a protective layer, 8 is a second magnetic generator, 9 is a second electron radiation source, 10 is a second quantum dot drug complex, 11 is a second controlled-release membrane, and 12 is a second release substrate.

[0063] Quantum dots are microparticles with discontinuous moving energy waves, possessing microparticle characteristics and high-frequency energy wave characteristics. Magnetic induction is easier and more convenient to operate compared to traditional methods such as oral administration, intravenous injection, and subcutaneous injection. It can improve patient compliance while avoiding the first-pass effect and drug side effects. The penetration process of magnetically induced drugs under the induction of an external magnetic field: 1) Lorentz force: Drug ions move into the skin tissue under the action of the Lorentz force in the magnetic field. 2) Magnetohydrodynamic motion: Water molecules flow under the influence of the external magnetic field to transport drugs, and the biological barrier permeability of the drugs is enhanced by applying a magnetic field to play a role. 3) Quantum dot materials are combined with magnetic nanoparticles to form magnetic quantum dot composite materials. Under the action of an external magnetic field, this composite material can move along the direction of the magnetic field lines, enabling precise drug delivery. The electronic radiation source emits far-infrared radiation with a wavelength range between 5 and 1000 μm after absorbing the heat of the human body, exciting the electron transition in the quantum dots, resulting in the emission of electromagnetic waves with specific wavelengths, which can form resonance and conduction with the magnetic field energy waves of human cells, correct the cells with chaotic magnetic field fluctuations, repair damaged cells, supplement cell energy, and improve human vitality. The present invention combines magnetic induction of quantum dots with magnetic field therapy and simultaneously adopts the design of a multi-pole magnetic circuit with parallel arrangement, greatly improving the treatment effect.

[0064] The present invention also provides a preparation method of the magnetically induced quantum dot patch described in the above technical solution, including the following steps:

[0065] The preparation method of the first patch includes the following steps:

[0066] Coat a first binder on the surface of the first substrate to obtain a bonding layer;

[0067] Mix the first permanent magnet material, the first rubber, the first resin, and the first additive and then mold them to obtain a magnetic field generation layer;

[0068] Mix polyvinylpyrrolidone, a glycerol solution of cross-linked polyvinylpyrrolidone, polyacrylic acid colloid, tartaric acid, the first electronic radiation source, water, and a cross-linking agent and then mold them to obtain an electronic radiation layer;

[0069] Stack the bonding layer, the magnetic field generator, and the electronic radiation layer in sequence, and then coat a first dispersion liquid on the surface of the electronic radiation layer to form a quantum dot drug composite layer; the first dispersion liquid includes the first quantum dots, a carrier, the first drug, and water;

[0070] Paste a controlled-release membrane layer and a first release liner on the surface of the quantum dot drug composite layer in sequence to obtain the first patch;

[0071] The preparation method of the second patch includes the following steps:

[0072] Coat a second binder on the surface of the second substrate to obtain a protective layer;

[0073] Mix the second permanent magnetic material, the second electron radiation source, the second rubber, the second resin and the second auxiliary agent and then form them into a shape to obtain a magnetic induction layer;

[0074] Mix the second quantum dots, the second drug, the sustained release agent and water and then form them into a shape to obtain a sustained release layer;

[0075] Stack the protective layer, the magnetic induction layer, the sustained release layer and the second release liner to obtain the second patch.

[0076] As a specific embodiment of the present invention, the preparation method of the first patch includes the following steps:

[0077] Coat a first adhesive on the surface of the first substrate to obtain an adhesive layer;

[0078] Mix the first permanent magnetic material, the first rubber, the first resin and the first auxiliary agent and then form them into a shape to obtain a magnetic field generating layer;

[0079] Mix a glycerol solution of polyvinylpyrrolidone and crosslinked polyvinylpyrrolidone, polyacrylic acid colloid, tartaric acid, the first electron radiation source, water and a crosslinking agent and then form them into a shape to obtain an electron radiation layer;

[0080] Stack the adhesive layer, the magnetic field generator and the electron radiation layer in sequence, and then coat a first dispersion liquid on the surface of the electron radiation layer to form a quantum dot drug composite layer; the first dispersion liquid includes the first quantum dots, a carrier, the first drug and water;

[0081] Paste a controlled release membrane layer and a first release liner on the surface of the quantum dot drug composite layer in sequence to obtain the first patch.

[0082] In the present invention, a first adhesive is coated on the surface of the first substrate to obtain an adhesive layer. As a specific embodiment of the present invention, the coating may include dot coating, and the coating amount of the dot coating may be 80-120 g / m 2 , specifically 80 g / m 2 , 85 g / m 2 , 90 g / m 2 , 95 g / m 2 , 100 g / m 2 , 105 g / m 2 , 110 g / m 2 , 115 g / m 2 or 120 g / m 2 .

[0083] The present invention mixes a first permanent magnetic material, a first rubber, a first resin, and a first auxiliary agent and then forms them to obtain a magnetic field generating layer. As a specific embodiment of the present invention, the first rubber may be natural rubber; the first resin may include chlorinated polyethylene resin; the first auxiliary agent may include dioctyl phthalate, sulfur, or titanate coupling agent; the mass ratio of the first permanent magnetic material, the first rubber, the first resin, and the first auxiliary agent may be 1:1.4-1.5:0.07-0.09:0.25-0.35, specifically 1:1.49:0.08:0.30.

[0084] As a specific embodiment of the present invention, before the mixing, it may further include: sieving the first permanent magnetic material and taking the undersize; the aperture of the sieve used for sieving may be 100 mesh or more, and may also be 100-150 mesh. As a specific embodiment of the present invention, the temperature of the mixing may be 80-100 °C, and may also be 90-95 °C. Mixing at a high temperature in the present invention can melt the materials, facilitating subsequent forming. As a specific embodiment of the present invention, the forming may be calendering forming. The present invention has no special limitation on the calendering forming as long as the required thickness can be achieved; the present invention can obtain a coil after forming. As a specific embodiment of the present invention, after the forming, it may further include magnetizing the formed product to obtain a magnetic field generating layer with the required magnetic induction intensity.

[0085] The present invention mixes a glycerol solution of polyvinylpyrrolidone and cross-linked polyvinylpyrrolidone, polyacrylic acid colloid, tartaric acid, a first electron radiation source, water, and a cross-linking agent and then forms them to obtain an electron radiation layer. As a specific embodiment of the present invention, the mass concentration of polyvinylpyrrolidone in the glycerol solution of polyvinylpyrrolidone and cross-linked polyvinylpyrrolidone may be 0.8-1.0%, specifically 0.9%; the mass concentration of cross-linked polyvinylpyrrolidone in the glycerol solution of polyvinylpyrrolidone and cross-linked polyvinylpyrrolidone may be 20-30%, specifically 25.0%; the water may be purified water; the cross-linking agent may include glycohydroxyaluminum. As a specific embodiment of the present invention, the mass ratio of the glycerol solution of polyvinylpyrrolidone and cross-linked polyvinylpyrrolidone, polyacrylic acid colloid, tartaric acid, a first electron radiation source, water, and the cross-linking agent may be 1:0.1-0.2:0.007-0.009:0.02-0.04:1.6-1.8:0.003-0.005, specifically 1:0.185:0.008:0.030:1.775:0.004.

[0086] As a specific embodiment of the present invention, the mixing may include the following steps:

[0087] Mix the glycerol solution of polyvinylpyrrolidone and cross-linked polyvinylpyrrolidone and water and perform a first stirring to obtain a first mixed solution;

[0088] After adding polyacrylic acid colloid, tartaric acid, graphene and a crosslinking agent to the first mixed solution, perform a second stirring.

[0089] In the present invention, the time of the first stirring can be 13 - 17 min, and can also be 15 - 16 min; the time of the second stirring can be 13 - 17 min, and can also be 15 - 16 min; the present invention has no special requirements for the rotation speeds of the first stirring and the second stirring, as long as they can be mixed evenly.

[0090] In the present invention, after the pH of a glycerol solution of polyvinylpyrrolidone and crosslinked polyvinylpyrrolidone, polyacrylic acid colloid, and water is adjusted with tartaric acid, a hydrocolloid is formed under the action of a crosslinking agent.

[0091] As a specific embodiment of the present invention, the forming can be coating the mixed system in a hydrocolloid coater to obtain a hydrocolloid as an electron radiation layer.

[0092] After obtaining the adhesive layer, the magnetic field generating layer, and the electron radiation layer, the present invention stacks the adhesive layer, the magnetic field generating layer, and the electron radiation layer in sequence and then coats a first dispersion liquid on the surface of the electron radiation layer to form a quantum dot drug composite layer. As a specific embodiment of the present invention, the stacking method can be compounding the adhesive layer and the magnetic field generating layer using a compounding machine and then pasting the electron radiation layer on the surface of the magnetic field generating layer. As a specific embodiment of the present invention, the first dispersion liquid includes a first quantum dot, a carrier, a first drug, and water; the mass ratio of the first quantum dot, the carrier, and the first drug can be 1:5 - 7:0.8 - 2, and can specifically be 1:5:0.8; the present invention has no special limitation on the amount of water used, as long as uniform dispersion can be achieved. As a specific embodiment of the present invention, the coating can be coating, and the present invention has no special limitation on the coating, and the conventional methods in the art can be used.

[0093] After obtaining the quantum dot drug composite layer, the present invention pastes a controlled release membrane layer and a first release substrate on the surface of the quantum dot drug composite layer in sequence to obtain the first patch. The present invention has no special limitation on the pasting, and the conventional methods in the art can be used.

[0094] As a specific embodiment of the present invention, the preparation method of the second patch includes the following steps:

[0095] Coat a second adhesive on the surface of the second substrate to obtain a protective layer;

[0096] Mix a second permanent magnetic material, ferrite, a second electron radiation source, a second rubber, a second resin, and a second additive and then form them to obtain a magnetic induction layer;

[0097] Mix the second quantum dots, the second drug, the sustained-release agent and water and then form them to obtain the sustained-release layer;

[0098] Stack the protective layer, the magnetic induction layer, the sustained-release layer and the second release substrate to obtain the second patch.

[0099] In the present invention, a second binder is coated on the surface of the second substrate to obtain the protective layer. As a specific embodiment of the present invention, the coating may include coating, and the coating amount of the coating may be 50-120 g / m 2 , specifically 50 g / m 2 , 55 g / m 2 , 60 g / m 2 , 65 g / m 2 , 70 g / m 2 , 75 g / m 2 , 80 g / m 2 , 85 g / m 2 , 90 g / m 2 , 95 g / m 2 , 100 g / m 2 , 105 g / m 2 , 110 g / m 2 , 115 g / m 2 or 120 g / m 2 .

[0100] In the present invention, the second permanent magnetic material, the second electron radiation source, the second rubber, the second resin and the second auxiliary agent are mixed and then formed to obtain the magnetic induction layer. As a specific embodiment of the present invention, the second rubber may be chloroprene rubber; the second resin may include epoxy resin; the second auxiliary agent may include adipate, zinc oxide or titanate coupling agent; the mass ratio of the second permanent magnetic material, the second electron radiation source, the second rubber, the second resin and the second auxiliary agent may be 30-33:4-6:48-52:2-3:8-12, specifically 32.5:5:50:2.5:10.

[0101] As a specific embodiment of the present invention, before mixing, it may further include: sieving the second permanent magnetic material and taking the undersize; the aperture of the sieve used for sieving may be 100 mesh or more, and may also be 100 - 150 mesh. As a specific embodiment of the present invention, the temperature of the mixing may be 80 - 100 °C, and may also be 90 - 95 °C. Mixing at a high temperature in the present invention can melt the materials, facilitating subsequent shaping. As a specific embodiment of the present invention, the shaping can be calendering. The present invention has no special limitation on the calendering, as long as the required thickness can be achieved; the present invention can obtain a coil after shaping. As a specific embodiment of the present invention, after shaping, it may further include magnetizing the shaped product to obtain a magnetic induction layer with the required magnetic induction intensity.

[0102] In the present invention, the second quantum dots, the second drug, the sustained-release agent and water are mixed and then shaped to obtain a sustained-release layer. As a specific embodiment of the present invention, the sustained-release agent may include ethylene-vinyl acetate copolymer (EVA), hydrocolloid or silicone gel; the mass ratio of the second quantum dots, the second drug, the sustained-release agent and water may be 8 - 12:5 - 7:240 - 260:48 - 52, and may specifically be 10:6:250:50. The present invention has no special limitation on the mixing, as long as they can be mixed evenly.

[0103] As a specific embodiment of the present invention, the coating can be coating. The present invention has no special limitation on the coating, and the conventional methods in the art can be adopted.

[0104] After obtaining the protective layer, the magnetic induction layer, and the sustained-release layer, the present invention stacks the protective layer, the magnetic induction layer, the sustained-release layer and the second release substrate to obtain the second patch. As a specific embodiment of the present invention, the stacking method may be to use a laminator to laminate the protective layer, the magnetic induction layer, the sustained-release layer and the second release substrate in sequence.

[0105] The present invention also provides the application of the magnetic induction quantum dot patch described in the above technical solution or the magnetic induction quantum dots prepared by the preparation method described in the above technical solution in the preparation of drugs for treating soft tissue injuries, promoting blood circulation to remove blood stasis, detumescence and pain relief, sarcoidosis, calming the nerves and hypnotizing, or relieving asthma and cough. As a specific embodiment of the present invention, when treating human diseases with the magnetic induction quantum dot patch, the affected area can be cleaned and dried first, and then the release film can be removed and the patch can be applied to the affected area. Figure 3 It is a schematic diagram of the magnetic field generated by the magnetic induction quantum dot patch provided by the present invention.

[0106] In order to further illustrate the present invention, the technical solutions provided by the present invention will be described in detail below with reference to the embodiments, but they cannot be understood as limiting the protection scope of the present invention.

[0107] Example 1

[0108] The adhesive layer is a PU dot-coated silicone gel, which has the advantage that the skin is breathable and not easily allergic when applied;

[0109] The second magnetic field generator uses a neodymium iron boron multi-pole permanent magnet, which is magnetized by a pulse magnetization method to a magnetic induction intensity of 30 mT. The magnetic field has multiple N and S poles distributed in parallel. The width of the N and S poles is 3 mm, forming a 50-pole magnetic circuit;

[0110] The electron radiation source uses graphene with an average particle size of 5 μm, which can generate far-infrared rays with wavelengths between 6 and 14 μm;

[0111] The quantum dots in the quantum dot drug complex are superparamagnetic Fe 3 O 4 @ alginate carbon quantum dots and doped zinc sulfide (ZnS) quantum dots, the carrier is liposome, and the drug is the essential oil of wormwood, a plant extract;

[0112] The controlled release membrane uses ethylene-vinyl acetate copolymer (EVA);

[0113] The release base material uses a release film;

[0114] The preparation method is as follows:

[0115] 1. Dot-coat silicone gel on a PU coil using a coater, with a coating amount of 100 g / m 2 , to make a silicone gel coil with a thickness of 0.18 mm as the adhesive layer;

[0116] 2. Pass the neodymium iron boron magnetic powder through a 100-mesh sieve and take the undersize; mix 100 kg of the sieved neodymium iron boron magnetic powder, 149 kg of natural rubber, 8 kg of chlorinated polyethylene resin, and 30 kg of dioctyl phthalate auxiliary agent at 90 °C, melt and mix them, then form them into a roll under a calender, and use a multi-pole pulse magnetizer to magnetize to a magnetic induction intensity of 30 mT, with the width of the N and S poles being 3 mm, to make a multi-pole magnetic circuit neodymium iron boron coil with a thickness of 0.5 mm as the magnetic field generation layer;

[0117] 3. Composite the silicone gel coil obtained in step 1 and the multi-pole magnetic circuit neodymium iron boron coil obtained in step 2 using a laminator, and die-cut with a die-cutting machine to obtain a laminated adhesive layer and magnetic field generation layer;

[0118] 4. Dissolve 60 g of polyvinylpyrrolidone and 1.7 kg of cross-linked polyvinylpyrrolidone in 5 kg of glycerol to obtain a glycerol solution of polyvinylpyrrolidone and cross-linked polyvinylpyrrolidone; then add 12.0 kg of purified water, mix and pour it into a stirrer, and perform the first stirring for 15 min to obtain a first mixed solution; add 1.25 kg of polyacrylic acid colloid, 54 g of tartaric acid, 203 g of graphene with a particle size of 5 μm, and 27 g of glyoxal aluminum (cross-linking agent) to the first mixed solution for the second stirring. After stirring for 15 min, coat it with a hydrocolloid coater, cut it, and make a graphene hydrocolloid with a thickness of 0.2 mm as the electron radiation layer.

[0119] 5. Paste the electron radiation layer on the surface of the magnetic field generation layer;

[0120] 6. Synthesize superparamagnetic Fe 3 O 4 @ alginate carbon quantum dots

[0121] (1). Prepare Fe 3 O 4 nanoparticles

[0122] a. Dissolve FeCl 3 ·6H 2 O and FeCl 2 ·4H 2 O in deionized water according to a molar ratio of 2:1.

[0123] b. Under nitrogen protection, stir and heat to 75 °C.

[0124] c. Slowly add ammonia water to adjust the pH value to 10 to form a black Fe 3 O 4 nanoparticle precipitate.

[0125] d. After magnetic separation, wash with deionized water and ethanol, and dry.

[0126] (2). Prepare alginate carbon quantum dots

[0127] a. Dissolve sodium alginate in deionized water.

[0128] b. Transfer the solution to a high-pressure reactor and react at 190 °C for 5 h.

[0129] c. After cooling to 30 °C, centrifuge to remove large particles to obtain an alginate carbon quantum dot solution.

[0130] (3). Composite of Fe 3 O 4 @ alginate carbon quantum dots

[0131] a. Add Fe 3 O 4The nanoparticles were dispersed in deionized water and ultrasonically treated.

[0132] b. Add the alginate carbon quantum dot solution and stir for 16 h.

[0133] c. After magnetic separation, wash with deionized water and dry to obtain superparamagnetic Fe 3 O 4 @alginate carbon quantum dots.

[0134] 7. Disperse 80 mg of superparamagnetic Fe 3 O 4 @alginate carbon quantum dots in 500 mg of liposomes, then mix with 80 mg of wormwood essential oil, and then add 20 mg of doped zinc sulfide (ZnS) quantum dots. Stir evenly and coat on the surface of the electron radiation layer to form a quantum dot drug composite layer with a thickness of 0.05 mm;

[0135] 8. Attach the cut ethylene-vinyl acetate copolymer (EVA) controlled release membrane with a thickness of 20 μm to the surface of the quantum dot drug composite layer;

[0136] 9. Attach the cut release film to the surface of the controlled release membrane layer to obtain a magnetically induced quantum dot patch.

[0137] The structural schematic diagram of the magnetically induced quantum dot patch prepared in Example 1 is as Figure 1 shown, where 1 is the adhesive layer, 2 is the magnetic generation layer, 3 is the electron radiation layer, 4 is the quantum dot drug composite layer, 5 is the controlled release membrane layer, and 6 is the first release substrate.

[0138] The patient is 83 years old, female, suffering from phlebitis for 24 years, taking medicine for a long time without improvement, with skin pigment accumulation and blackening. Applying the traditional Jin Yuetang brand acupoint pressure stimulation patch did not improve the condition, and there was swelling and unbearable itching in the calf. After the patient applied the magnetically induced quantum dot patch of Example 1 for 24 h, most of the black pigment on the skin at the patch application site disappeared. After 48 h, the subcutaneous exudate was absorbed, and the calf was no longer swollen and itchy.

[0139] When the patient uses the patch for treating human diseases with the magnetically induced quantum dot patch, first clean and dry the diseased area, then remove the release film and apply it to the diseased area. The edge of the adhesive layer directly contacts the skin for adhesion, so that the quantum dot drug composite is in close contact with the skin. The electromagnetic field generated by the multi-pole magnetic circuit drives the superparamagnetic Fe 3 O 4The drug carried by alginate carbon quantum dots and wormwood extract penetrates through the skin and enters human tissues. Graphene emits far-infrared rays after absorbing human body heat, which stimulates the doped zinc sulfide (ZnS) quantum dots to emit electromagnetic waves, causing the wormwood extract to be released and producing a medicinal effect; human tissue cells receive the electromagnetic waves emitted by the quantum dots, producing a therapeutic effect; the electromagnetic field generated by the multi-pole magnetic circuit has a magnetic therapy effect on human tissues. The above synergistic effects enable the rapid recovery of human diseased tissues.

[0140] Example 2

[0141] The protective layer is coated with acrylic using a PVC composite film;

[0142] The magnetic field generator is made of neodymium iron boron and ferrite to form a flexible multi-pole permanent magnet;

[0143] The electronic radiation source uses far-infrared ceramic powder;

[0144] The quantum dot drug complex uses graphene quantum dots, which have excellent photoluminescence (PL) properties, low toxicity, superior biocompatibility, and a large specific surface area that helps with drug delivery.

[0145] The sustained-release agent uses silicone gel;

[0146] The release liner substrate uses a release film.

[0147] The preparation method is as follows:

[0148] 1. Coating acrylic on a coating machine using a PVC composite material coil, with a coating amount of 50 g / m 2 , to make an acrylic medical adhesive tape coil with a thickness of 0.2 mm as the protective layer;

[0149] 2. Pass the neodymium iron boron magnetic powder through a 100-mesh sieve and take the undersize; by mass percentage, mix 5% of the sieved neodymium iron boron magnetic powder, 27.5% of ferrite, 5% of far-infrared ceramic powder with a particle size of 3 μm, 50% of chloroprene rubber, 2.5% of epoxy resin, and 10% of adipate ester additives at 90 °C, then melt and mix them and form them into a roll under a calender, and use a pulse magnetizer to multi-pole magnetize to a magnetic induction intensity of 20 mT, with the widths of the N pole and S pole being 2 mm, to make a neodymium iron boron ferrite multi-pole magnetic circuit coil with a thickness of 0.5 mm containing far-infrared ceramic powder as the magnetic induction layer;

[0150] 3. Dissolve 100 mg of graphene quantum dots in 500 mg of water, then add 60 mg of NSAIDs drug to 2500 mg of silicone gel and mix to obtain a dispersion;

[0151] 4. Coat the dispersion prepared in step 3 using a coating machine to make a quantum dot silicone gel coil with a thickness of 0.5 mm as the sustained-release layer;

[0152] 5. Arrange the acrylic medical adhesive tape coil, the neodymium iron boron ferrite multi-pole magnetic circuit coil containing far-infrared ceramic powder, the quantum dot silicone gel coil, and the release film coil in sequence with a laminator, and die-cut with a die-cutting machine to obtain the magnetic induction quantum dot patch.

[0153] Example 2 Combine the magnetic field generator and the electron radiation source into one coil, and also combine the quantum dot drug complex and the controlled release membrane into one coil, which simplifies the production process, enables large-scale automated production, reduces labor, and improves productivity.

[0154] The schematic structural diagram of the magnetic induction quantum dot patch prepared in Example 2 is as Figure 2 shown, where 7 is the protective layer, 8 is the second magnetic generator, 9 is the second electron radiation source, 10 is the second quantum dot drug complex, 11 is the second controlled release membrane, and 12 is the second release substrate.

[0155] The patient is 36 years old, male. When riding a bicycle, he collided with an electric scooter, resulting in partial soft tissue injury and large-area bruising on the thigh. 48 hours after the collision, the magnetic induction quantum dot patch of Example 2 was applied. After 24 hours of application, 80% of the bruising at the application site disappeared. After 48 hours, the skin color at the application site was the same as the normal skin color, and the bruising at the non-applied site was still obvious.

[0156] When the patient uses the magnetic induction quantum dot patch for treatment, first clean and dry the affected area, then remove the release film and apply it to the affected area. At this time, the slow-release layer is in close contact and adhesion with the skin. The far-infrared ceramic powder emits far-infrared after absorbing the heat of the human body, exciting the graphene quantum dots to emit electromagnetic waves, and the human tissue cells produce a therapeutic effect after receiving them; the electromagnetic field generated by the multi-pole magnetic circuit drives the drug to penetrate through the skin and enter the human tissue, producing a drug treatment effect; the electromagnetic field generated by the multi-pole magnetic circuit has a magnetic therapy effect on the human tissue. The above synergistic effects enable the rapid recovery of the diseased human tissue.

[0157] Although the above embodiments have made a detailed description of the present invention, they are only a part of the embodiments of the present invention, not all embodiments. People can also obtain other embodiments based on these embodiments without creative efforts, and these embodiments all fall within the protection scope of the present invention.

Claims

1. A magnetically introduced quantum dot patch, characterized in that: including a first application or a second application; The first patch comprises an adhesive layer and a magnetic field generating layer, an electron radiation layer, a quantum dot drug complex layer, a controlled release membrane layer and a first release substrate stacked in sequence; the middle portion of the adhesive layer contacts the magnetic field generating layer, and the edge portion of the adhesive layer covers the side surfaces of the magnetic field generating layer, the electron radiation layer, the quantum dot drug complex layer and the controlled release membrane layer and the remaining upper surface of the first release substrate; the quantum dot drug complex layer comprises a first quantum dot drug complex, the first quantum dot drug complex comprises a carrier and a complex loaded on the surface of the carrier, and the complex comprises a first quantum dot and a first drug combined with the first quantum dot; The second patch includes a protective layer, a magnetic introduction layer, a sustained-release layer and a second release substrate stacked in sequence; the magnetic introduction layer includes a second magnetic field generator and a second electron radiation source dispersed in the second magnetic field generator; the sustained-release layer includes a second controlled-release membrane and a second quantum dot drug complex dispersed in the second controlled-release membrane, and the second quantum dot drug complex includes a second quantum dot and a second drug combined with the second quantum dot.

2. The magnetic introduction quantum dot patch according to claim 1, characterized in that: The adhesive layer includes a first substrate and a first adhesive coated on the surface of the first substrate, the first substrate includes non-woven fabric, polyurethane, polyethylene or polyvinyl chloride; the first adhesive includes a pressure-sensitive adhesive, acrylic adhesive, silicone gel or hydrogel; The protective layer includes a second substrate and a second adhesive coated on the surface of the second substrate, wherein the second substrate includes non-woven fabric, polyurethane, polyethylene or polyvinyl chloride; and the second adhesive includes pressure-sensitive adhesive, acrylic adhesive, silicone gel or hydrogel.

3. The magnetic introduction quantum dot patch according to claim 1, characterized in that: The magnetic field generating layer comprises a first magnetic field generator; the first magnetic field generator and the second magnetic field generator respectively comprise permanent magnetic materials; The first magnetic field generator and the second magnetic field generator each include a multi-pole magnetic circuit, and the number of poles of the magnetic circuit is more than 4; The magnetic induction intensities of the first magnetic field generator and the second magnetic field generator are independently 5 to 100 mT.

4. The magnetic introduction quantum dot patch according to claim 1, characterized in that: The electron radiation layer includes a first electron radiation source; the first electron radiation source and the second electron radiation source independently include one or more of far-infrared ceramic powder, tourmaline and graphene.

5. The magnetic introduction quantum dot patch according to claim 1, characterized in that: The first quantum dots and the second quantum dots independently include one or more of ferrous sulfide quantum dots, superparamagnetic Fe3O4@alginate carbon quantum dots, doped zinc sulfide quantum dots, perovskite quantum dots, silver chalcogenide quantum dots, indium copper sulfide quantum dots, iron sulfide quantum dots, carbon quantum dots, graphene quantum dots and ferrite quantum dots; The ligands in the first quantum dot and the second quantum dot independently include thioglycolic acid, mercaptoethylamine or polyethylene glycol; The first drug and the second drug independently include plant extracts, tramadol, NSAIDs, melatonin, and salbutamol; The carrier includes hydrogel, liposome, lactic acid-glycolic acid copolymer nanosphere or poly D, L-lactic acid nanosphere.

6. The magnetic introduction quantum dot patch according to claim 1, characterized in that: The controlled release membrane layer includes a first controlled release membrane, and the first controlled release membrane includes a polypropylene stretched microporous membrane; The material of the second controlled-release membrane includes ethylene-vinyl acetate copolymer, hydrocolloid or silicone gel.

7. The method for preparing the magnetically introduced quantum dot patch according to any one of claims 1 to 6, characterized in that: The following steps are involved: The preparation method of the first dressing comprises the following steps: Coating a first adhesive on the surface of the first substrate to obtain an adhesive layer; The first permanent magnetic material, the first rubber, the first resin and the first auxiliary agent are mixed and molded to obtain a magnetic field generating layer; The glycerol solution of polyvinyl pyrrolidone and cross-linked polyvinylpyrrolidone, polyacrylic acid colloid, tartaric acid, a first electron radiation source, water and a cross-linking agent are mixed and molded to obtain an electron radiation layer; After the bonding layer, the magnetic field generator and the electron radiation layer are stacked in sequence, a first dispersion is coated on the surface of the electron radiation layer to form a quantum dot drug complex layer; the first dispersion comprises first quantum dots, a carrier, a first drug and water; Sequentially pasting a controlled release membrane layer and a first release substrate on the surface of the quantum dot drug complex layer to obtain the first patch; The preparation method of the second dressing comprises the following steps: Coating a second adhesive on the surface of the second substrate to obtain a protective layer; The second permanent magnetic material, the second electron radiation source, the second rubber, the second resin and the second auxiliary agent are mixed and molded to obtain a magnetic introduction layer; The second quantum dots, the second drug, the sustained-release agent and water are mixed and molded to obtain a sustained-release layer; The protective layer, the magnetic guide layer, the slow-release layer and the second release substrate are stacked to obtain the second patch.

8. The preparation method according to claim 7, characterized in that: The first resin includes a chlorinated polyethylene resin; The first auxiliary agent includes dioctyl phthalate, sulfur or titanate coupling agent; The cross-linking agent includes aluminum glycol hydroxide.

9. The preparation method according to claim 7, characterized in that: The second resin includes epoxy resin; The second auxiliary agent includes adipic acid ester, zinc oxide or titanate coupling agent; The sustained-release agent includes ethylene-vinyl acetate copolymer, hydrocolloid or silicone gel.

10. Use of the magnetically introduced quantum dot patch according to any one of claims 1 to 6 or the magnetically introduced quantum dots prepared by the preparation method according to any one of claims 7 to 9 in the preparation of drugs for treating soft tissue injuries, promoting blood circulation and removing blood stasis, reducing swelling and relieving pain, sarcoidosis, tranquilizing the nerves and hypnotizing, or relieving asthma and cough.

Images